Dr. Tse-Wen Chang, founder and chairman of Immunwork and T‑E Meds, shared the latest developments of both companies on 15th January. He also announced that TE-Pharma Holding plans to launch an IPO in 2026.
Immunwork has developed two ultra-long-acting drugs: TE‑8105 and TE‑8214. TE‑8105 primarily targets type 2 diabetes, obesity, and fatty liver disease, and is scheduled to complete Phase 2a clinical trials this year. TE‑8214 focuses on neuroendocrine tumors and acromegaly, with Phase 1 clinical trials also set to be completed this year. Meanwhile, two antibody-drug conjugates (ADCs) developed by T-E Meds are planned to enter clinical trials in 2026.
As Immunwork enters its 11th year, the company has demonstrated its technical maturity, successfully developing multiple competitive products targeting major diseases. Its future prospects look promising.
News website links: